2cureX is a biotechnology company focused on improving cancer treatment by tailoring therapies to individual patients. The company operates in the healthcare sector, specifically targeting the oncology market. Its primary clients are healthcare providers, including hospitals and cancer treatment centers, who seek to enhance the effectiveness of cancer therapies for their patients.

2cureX's core product is IndiTreat®, a diagnostic tool that helps doctors determine the most effective cancer treatment for each patient. This tool works by testing multiple cancer treatments on a patient's tumor cells outside the body, identifying which treatment is likely to be the most effective. This personalized approach aims to improve treatment outcomes and reduce unnecessary side effects.

The company generates revenue through the sale of its IndiTreat® tests to healthcare providers. Additionally, 2cureX engages in partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements or joint research projects. These collaborations can provide additional revenue streams and help expand the company's market reach.

2cureX operates primarily in Europe but aims to expand its presence globally. The company recently completed a directed issue, raising approximately SEK 40 million. This funding will support further development and commercialization of IndiTreat®, as well as expansion into new markets.

In summary, 2cureX is a biotech firm dedicated to personalizing cancer treatment, serving healthcare providers with its innovative diagnostic tool, IndiTreat®. The company makes money through test sales and strategic partnerships, and it is focused on expanding its market presence.

Keywords: biotechnology, cancer treatment, personalized medicine, diagnostic tool, healthcare, oncology, IndiTreat®, revenue, partnerships, Europe.